Actively Recruiting
Study of Treatment Adherence to CDK46 Inhibitors Combined with Endocrine Therapy for Early HRHER2- Breast Cancer at High Recurrence Risk
Led by University Hospital, Grenoble · Updated on 2026-10-02
81
Participants Needed
1
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adherence to cell cycle inhibitors combined with endocrine therapy in patients with hormone receptor-positive HR and HER2-negative early breast cancer at high risk of recurrence. This observational study aims to understand how well patients follow their prescribed treatment plans involving drugs like abemaciclib or ribociclib alongside standard endocrine therapy. The importance of adherence is highlighted by the increased risk of cancer recurrence and mortality associated with poor treatment compliance. Participants will receive adjuvant endocrine therapy combined with a CDK46 inhibitor such as abemaciclib or ribociclib. Treatment durations are planned for 24 months for abemaciclib and 36 months for ribociclib. The study will monitor initiation rates, early discontinuation defined as stopping treatment before 20 months for abemaciclib or before 30 months for ribociclib, dose modifications, and reasons for any changes in therapy. This real-world study also aims to identify risk factors for non-adherence and assess invasive disease-free survival. During the study, participants treatment adherence will be closely observed, and data on dose adjustments and treatment discontinuation will be collected. Researchers will evaluate outcomes such as treatment completion rates and survival free from invasive disease. The study will take place over several years, starting in 2026 and ending in 2031, with follow-up assessments aligned with treatment duration. Patients must have undergone curative surgery and, if indicated, radiotherapy prior to treatment initiation. The study is sponsored by University Hospital, Grenoble.
CONDITIONS
Brief Title
Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence.
Research Team
E
Emmanuelle JACQUET, MD, PhD
A
Adrien MONARD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here